Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2022 | 06-2022 | 03-2022 | 12-2021 | 09-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,491,300 | 3,395,100 | 3,345,700 | 2,885,600 | 3,432,400 |
| Marketable Securities | 3,530,400 | 4,171,300 | 3,704,900 | 2,809,100 | 2,355,200 |
| Receivables | 5,548,300 | 5,161,400 | 4,839,000 | 6,036,500 | 5,452,000 |
| Inventories | 2,412,200 | 2,218,500 | 1,991,500 | 1,951,300 | 2,053,800 |
| TOTAL | $15,428,600 | $15,529,900 | $14,306,000 | $14,014,900 | $13,775,400 |
| Non-Current Assets | |||||
| PPE Net | 3,704,200 | 3,637,700 | 3,556,400 | 3,482,200 | 3,395,700 |
| Investments And Advances | 5,968,600 | 6,415,900 | 7,084,000 | 6,838,000 | 5,631,300 |
| Intangibles | 804,100 | 0 | 0 | 6,700 | 0 |
| Other Non-Current Assets | 1,772,300 | 1,622,300 | 1,402,300 | 1,093,000 | 869,101 |
| TOTAL | $12,249,200 | $11,675,900 | $12,042,700 | $11,419,900 | $9,896,101 |
| Total Assets | $27,677,800 | $27,205,800 | $26,348,700 | $25,434,800 | $23,671,500 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 535,600 | 534,200 | 470,300 | 564,000 | 427,000 |
| Other current liabilities | 1,796,400 | 1,933,400 | 2,046,000 | 2,206,800 | 2,061,000 |
| TOTAL | $2,879,200 | $3,033,900 | $3,007,600 | $3,932,500 | $3,714,800 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,981,100 | 1,980,700 | 1,980,400 | 1,980,000 | 1,979,600 |
| Deferred Revenues | 547,200 | 566,300 | 491,300 | 442,000 | 507,800 |
| Other Non-Current Liabilities | 598,600 | 724,700 | 692,500 | 680,200 | 662,600 |
| TOTAL | $3,359,800 | $3,484,100 | $3,426,400 | $2,733,500 | $2,698,700 |
| Total Liabilities | $6,239,000 | $6,518,000 | $6,434,000 | $6,666,000 | $6,413,500 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 108,902 | 109,008 | 109,846 | 108,539 | 107,543 |
| Common Shares | 100 | 100 | 100 | 100 | 100 |
| Retained earnings | 22,109,600 | 20,793,900 | 19,941,800 | 18,968,300 | 16,739,300 |
| Other shareholders' equity | -275,100 | -223,400 | -170,300 | -26,100 | 9,300 |
| TOTAL | $21,438,800 | $20,687,800 | $19,914,700 | $18,768,800 | $17,258,000 |
| Total Liabilities And Equity | $27,677,800 | $27,205,800 | $26,348,700 | $25,434,800 | $23,671,500 |